Agents that inhibit the bioactivity of vascular endothelial growth factor (VEGF) have dramatically improved visual acuity outcomes in a number of otherwise blinding eye diseases, including diabetic retinopathy, age-related macular degeneration, neovascular glaucoma and retinal vein occlusions [1, 2]. This evidence concerns the gene VEGFA and neovascular glaucoma.